Syros to Host Key Opinion Leader Webcast Series on Targeted Hematology Portfolio
May 19 2021 - 8:31AM
Business Wire
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development
of medicines that control the expression of genes, today announced
that it plans to host a three-part key opinion leader (KOL) webcast
series on its portfolio of investigational targeted therapies in
hematology. The series will consist of presentations from Syros
leaders, as well as KOLs, who will review recent progress for
SY-1425 in newly diagnosed higher-risk myelodysplastic syndrome
(MDS) and newly diagnosed unfit acute myeloid leukemia (AML) and
for SY-2101 in acute promyelocytic leukemia (APL), and discuss the
unmet need and evolving treatment landscape in these diseases. Each
event will be webcast live on Investors & Media section of the
Syros website at www.syros.com. An archived replay will be
available for approximately 30 days following each
presentation.
The Targeted Hematology Portfolio KOL Webcast Series schedule
will be as follows:
SY-1425 in Newly Diagnosed HR-MDS:
- Date: Wednesday, May 26
- Time: 8:30-10:00am ET
- Guest Speaker: Amy DeZern, M.D.,
M.H.S., Director, Bone Marrow Failure and MDS Program and Associate
Professor of Oncology, Johns Hopkins University
SY-1425 in Newly Diagnosed Unfit AML:
- Date: Tuesday, June 22
- Time: 8:30-10:00am ET
- Guest Speaker: Daniel Pollyea,
M.D., M.S., Associate Professor of Medicine, Clinical Director of
Leukemia Services and Robert H. Allen MD Chair in Hematology
Research, University of Colorado School of Medicine
SY-2101 in APL:
- Date: Tuesday, July 20
- Time: 8:30-10:00am ET
- Guest Speaker: Farhad Ravandi,
M.D., Janiece and Stephen A. Lasher Professor of Medicine, Chief of
Section of Acute Myeloid Leukemia, Department of Leukemia at The
University of Texas – MD Anderson Cancer Center
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the
expression of genes. Based on its unique ability to elucidate
regulatory regions of the genome, Syros aims to develop medicines
that provide a profound benefit for patients with diseases that
have eluded other genomics-based approaches. Syros is advancing a
robust clinical-stage pipeline, including: SY-1425, a
first-in-class oral selective RARα agonist in RARA-positive
patients with higher-risk myelodysplastic syndrome and acute
myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in
patients with acute promyelocytic leukemia; and SY-5609, a highly
selective and potent oral CDK7 inhibitor in patients with select
solid tumors. Syros also has multiple preclinical and discovery
programs in oncology and monogenic diseases. For more information,
visit www.syros.com and follow us on Twitter (@SyrosPharma) and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210519005002/en/
Media Contact: Naomi Aoki Syros Pharmaceuticals
617-283-4298 naoki@syros.com
Investor Contact: Hannah Deresiewicz Stern Investor
Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2023 to Apr 2024